Pathways To Access & Reimbursement

We are re-imagining this essential forum from a live in-person event to an interactive virtual format, designed to bring clarity to some of the greatest challenges facing manufacturers, patients, and payers alike in this radically altered healthcare climate.

Sweeping changes are coming to how drugs are priced, procured and reimbursed in Canada but many of the details have yet to be solidified. While the industry grapples with these ongoing changes, a global pandemic has created a new focal point: identifying viable COVID-19 treatments and supporting scientific advancements towards vaccine.

It’s a critical time for stakeholders to come together and learn about how regulatory bodies could potentially work together under a National Drug Agency and the implications of new pricing ceilings.

At this juncture, collaboration and transparency are paramount to patient access and improved health outcomes. Join us this February and to build your pricing and access strategy for 2020 and beyond through conversations and in-depth analysis about:

• OPTIMIZING pCPA negotiations with advice on current and impending policy positions
• UNDERSTANDING how PMPRB reform and National Pharmacare models could impact the Canadian market
• ASSESSING the emergence of new HTA frameworks
• IDENTIFY OPPORTUNITIES to create partnerships and advance your market access strategy